新型微网覆膜支架CGuard在颈动脉支架置入术中的安全性与有效性:单中心早期经验
本研究纳入82例接受CGuard支架颈动脉支架置入术的患者,评估其技术成功与临床成功。即刻技术成功率为100%,症状性患者围术期临床成功率为100%,无症状患者为98.5%。术后30天无新发事件,亚组DW-MRI显示23.8%患者出现新发缺血性脑病灶。
要点
- CGuard支架即刻技术成功率达100%,狭窄直径从81.4±4.9%降至11.0±3.5%。
- 围术期症状性患者临床成功率为100%,无症状患者为98.5%。
- 术后30天无新发事件,亚组DW-MRI新发缺血性脑病灶发生率为23.8%。
核心结论
- 单中心研究显示CGuard支架在症状性和无症状患者中安全有效,且不依赖主动脉弓解剖结构。
- 需要更大规模的对照研究来确认这些获益。
研究设计与样本
- 单中心前瞻性研究,纳入82例自2015年6月起接受CGuard支架颈动脉支架置入术的连续患者。
- 所有手术由同一位外科医生完成,主要终点为技术成功和临床成功(无死亡、大或小卒中)。
主要发现
- 即刻技术成功率为100%,狭窄直径从81.4±4.9%降至11.0±3.5%。
- 围术期症状性患者临床成功率为100%,无症状患者为98.5%(1例术后4小时急性支架血栓形成继发小卒中)。
- 术后30天无新发事件。
- 最近21例(24%)患者围术期DW-MRI显示23.8%出现新发缺血性脑病灶,平均病灶体积为0.039±0.025 cm3。
临床怎么用
- CGuard支架可用于症状性和无症状患者的颈动脉支架置入术,早期结果显示安全有效。
局限性
- 单中心研究,样本量有限。
- 需要更大规模的对照研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: Plaque protrusion through stent struts represents one of the principal causes of cerebral embolisation during carotid artery stenting (CAS) and the stent healing period. The aim of this study was to evaluate the safety (technical success) and efficacy (clinical success) of the CGuard stent system - a new nitinol stent covered by a closed-cell polyethylene terephthalate mesh designed to prevent embolic events. METHODS: Eighty-two consecutive patients who underwent CAS with CGuard from June 2015 were included in this study. The same surgeon performed all procedures. Primary endpoints included technical and clinical success. Clinical success was considered to be absence of death, major or minor stroke. The incidence of new ischaemic brain lesions was also evaluated by diffusion weighted magnetic resonance imaging (DW-MRI) in a subgroup of patients as a secondary endpoint. RESULTS: In this study, 82 patients (73.8 ± 8.5 years, 75% male, 19% symptomatic) underwent CAS procedures. Immediate technical success was 100%, with the stenosis diameter reduced from 81.4 ± 4.9% to 11.0 ± 3.5%. There was peri-operative technical and clinical success in 100% of symptomatic patients, and in 98.5% of asymptomatic patients, because of the occurrence of one acute stent thrombosis 4 hours post-CAS followed by a minor stroke. In the post-operative period (30 days), no new events were registered. The most recent 21 patients (24%) underwent DW-MRI in the peri-operative period: new ischaemic brain lesions were recorded in 23.8% of patients and the average lesion volume per patients was 0.039 ± 0.025 cm3. CONCLUSIONS: The technical and clinical outcomes of this single centre study suggest that the CGuard may be a safe and effective device for endovascular treatment of symptomatic and asymptomatic subjects, independent of aortic arch anatomy. Further larger comparative studies are needed to confirm these benefits.
引用
- Casana R, Tolva V, Odero A, et al. Safety and Efficacy of the New Micromesh-Covered Stent CGuard in Patients Undergoing Carotid Artery Stenting: Early Experience From a Single Centre. Eur J Vasc Endovasc Surg. 2017. PMID: 29089282. doi:10.1016/j.ejvs.2017.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。